Ensuring Patient Access to Critical Breakthrough Products Act of 2025
Sponsor
Full profile: /officials/Y000064
Source: Congress.gov · FEC
Cosponsors (5)
Members who have signed on to support this bill since introduction. Source: Congress.gov.
5 cosponsors on record at Congress.gov. The named list is syncing into Govwatch and will appear here shortly — view on Congress.gov in the meantime.
Latest Action
The most recent step in the bill's legislative path. Committee Activity below shows referrals and reports; the full action-by-action history including floor proceedings lives at Congress.gov →
Committee Activity
Previously
- Senate Committee on FinanceReferred To · 2025-05-12
Plain-English Summary
The legislation would allow patients faster access to certain new drugs and medical devices that show promise in treating serious or life-threatening conditions, even before they complete all standard FDA approval testing. This could benefit patients with diseases like cancer or rare conditions who have limited treatment options, though it may involve some additional risk since these products haven't undergone the full approval process. The changes would primarily affect pharmaceutical and medical device companies, patients, and the FDA's approval procedures.
AI-assisted summary generated from the official bill metadata (title, subjects, actions) sourced from Congress.gov. Cached and reviewed. Always verify against the official text linked below.
Subjects
Related legislation
Bills by the same sponsor or covering overlapping subjects.
- S5346EGG SAVE Act of 2026Referred to Committee · 2026-08-06
- S3333Emergency Savings Enhancement Act of 2025Reported by Committee · 2026-08-05
- S5198Build to Scale Reauthorization Act of 2026Referred to Committee · 2026-07-30
- S5150SAFE ActReferred to Committee · 2026-07-28